Journal article
Tecadenoson: a novel, selective A1 adenosine receptor agonist
Cardiology in review, Vol.13(6), pp.315-321
11/2005
DOI: 10.1097/01.crd.0000181621.84565.9d
PMID: 16230891
Abstract
Tecadenoson is a novel selective A1 adenosine receptor agonist that is currently being evaluated for the conversion of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm. By selectively targeting the A1 receptor, tecadenoson may be associated with fewer adverse effects such as flushing, dyspnea, chest discomfort, and hypotension than adenosine, which is a nonselective agonist of all 4 adenosine receptors. Based on the results of phase I and phase II clinical trials, tecadenoson appears to be an effective agent for producing rapid and sustained conversion of PSVT to sinus rhythm. Additionally, the adverse effects that are typically attributed to adenosine's nonselective stimulation of the A2A, A2B, and A3 receptors appear to occur less frequently with the use of tecadenoson. Tecadenoson also appears to be associated with a lower incidence of atrial fibrillation following conversion of PSVT compared with the rates that have been associated with adenosine in the literature. A randomized, prospective trial will need to be conducted in the future to appropriately compare the safety and efficacy of tecadenoson and adenosine.
Details
- Title: Subtitle
- Tecadenoson: a novel, selective A1 adenosine receptor agonist
- Creators
- Carla Peterman - University of Maryland, BaltimoreCynthia A Sanoski - University of the Sciences
- Resource Type
- Journal article
- Publication Details
- Cardiology in review, Vol.13(6), pp.315-321
- DOI
- 10.1097/01.crd.0000181621.84565.9d
- PMID
- 16230891
- ISSN
- 1061-5377
- eISSN
- 1538-4683
- Language
- English
- Date published
- 11/2005
- Academic Unit
- Pharmacy; Pharmacy Practice and Science
- Record Identifier
- 9984721125802771
Metrics
2 Record Views